Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates
Abstract
:1. Introduction
2. Materials and Methods
2.1. Subjects
2.2. BQT
2.3. Statistical Analysis
3. Results
3.1. Characteristics
3.2. Eradication Rates
3.2.1. Eradication Rates by Year
3.2.2. Eradication Rates by Treatment Duration
3.3. Factors Related to Eradication Failure
3.4. Adverse Events
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Crowe, S.E. Helicobacter pylori Infection. N. Engl. J. Med. 2019, 380, 1158–1165. [Google Scholar] [CrossRef] [PubMed]
- Quach, D.T.; Hiyama, T. Assessment of Endoscopic Gastric Atrophy according to the Kimura-Takemoto Classification and Its Potential Application in Daily Practice. Clin. Endosc. 2019, 52, 321–327. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gravina, A.G.; Priadko, K.; Ciamarra, P.; Granata, L.; Facchiano, A.; Miranda, A.; Dallio, M.; Federico, A.; Romano, M. Extra-Gastric Manifestations of Helicobacter pylori Infection. J. Clin. Med. 2020, 9, 3887. [Google Scholar] [CrossRef]
- Lee, Y.C.; Chiang, T.H.; Chou, C.K.; Tu, Y.K.; Liao, W.C.; Wu, M.S.; Graham, D.Y. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology 2016, 150, 1113–1124.e5. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kato, M.; Ota, H.; Okuda, M.; Kikuchi, S.; Satoh, K.; Shimoyama, T.; Suzuki, H.; Handa, O.; Furuta, T.; Mabe, K.; et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition. Helicobacter 2019, 24, e12597. [Google Scholar] [CrossRef]
- Chey, W.D.; Leontiadis, G.I.; Howden, C.W.; Moss, S.F. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am. J. Gastroenterol. 2017, 112, 212–239. [Google Scholar] [CrossRef]
- Kim, S.G.; Jung, H.K.; Lee, H.L.; Jang, J.Y.; Lee, H.; Kim, C.G.; Shin, W.G.; Shin, E.S.; Lee, Y.C. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J. Gastroenterol. Hepatol. 2014, 29, 1371–1386. [Google Scholar] [CrossRef]
- Jung, H.K.; Kang, S.J.; Lee, Y.C.; Yang, H.J.; Park, S.Y.; Shin, C.M.; Kim, S.E.; Lim, H.C.; Kim, J.H.; Nam, S.Y.; et al. Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020. Gut Liver 2021. [Google Scholar] [CrossRef] [PubMed]
- Malfertheiner, P.; Megraud, F.; O’Morain, C.A.; Gisbert, J.P.; Kuipers, E.J.; Axon, A.T.; Bazzoli, F.; Gasbarrini, A.; Atherton, J.; Graham, D.Y.; et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017, 66, 6–30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, J.Y.; Kim, N.; Nam, R.H.; In Choi, S.; Lee, J.W.; Lee, D.H. Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018. Helicobacter 2019, 24, e12660. [Google Scholar] [CrossRef] [PubMed]
- Lee, J.H.; Ahn, J.Y.; Choi, K.D.; Jung, H.Y.; Kim, J.M.; Baik, G.H.; Kim, B.W.; Park, J.C.; Jung, H.K.; Cho, S.J.; et al. Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: A prospective multicenter study. Helicobacter 2019, 24, e12592. [Google Scholar] [CrossRef]
- Lee, J.Y.; Kim, N.; Kim, M.S.; Choi, Y.J.; Lee, J.W.; Yoon, H.; Shin, C.M.; Park, Y.S.; Lee, D.H.; Jung, H.C. Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. Dig. Dis. Sci. 2014, 59, 1235–1243. [Google Scholar] [CrossRef]
- Megraud, F.; Coenen, S.; Versporten, A.; Kist, M.; Lopez-Brea, M.; Hirschl, A.M.; Andersen, L.P.; Goossens, H.; Glupczynski, Y. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013, 62, 34–42. [Google Scholar] [CrossRef] [PubMed]
- Boyanova, L.; Mitov, I. Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev. Anti-Infect. Ther. 2010, 8, 59–70. [Google Scholar] [CrossRef] [PubMed]
- Shin, W.G.; Lee, S.W.; Baik, G.H.; Huh, K.C.; Lee, S.I.; Chung, J.W.; Jung, W.T.; Park, M.I.; Jung, H.K.; Kim, H.U.; et al. Eradication Rates of Helicobacter pylori in Korea Over the Past 10 years and Correlation of the Amount of Antibiotics Use: Nationwide Survey. Helicobacter 2016, 21, 266–278. [Google Scholar] [CrossRef]
- Kim, G.H.; Kim, J.A.; Ko, U.W.; Park, J.H.; Lee, J.Y.; Jin, S.S.; Joo, Y.-H.; Shin, J.U. Eradication Rates of First-line and Second-line Therapy forHelicobacter pyloriInfection in Gyeongnam Province. Korean J. Helicobacter Up. Gastrointest. Res. 2015, 15. [Google Scholar] [CrossRef]
- Hwang, J.J.; Lee, D.H.; Lee, A.R.; Yoon, H.; Shin, C.M.; Park, Y.S.; Kim, N. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication. World J. Gastroenterol. 2015, 21, 8132–8139. [Google Scholar] [CrossRef]
- Graham, D.Y.; Fischbach, L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010, 59, 1143–1153. [Google Scholar] [CrossRef]
- Lee, J.Y.; Kim, N. Future trends of Helicobacter pylori eradication therapy in Korea. Korean J. Gastroenterol. 2014, 63, 158–170. [Google Scholar] [CrossRef]
- Yoon, K.; Kim, N.; Lee, J.W.; Yoon, H.; Shin, C.M.; Park, Y.S.; Lee, D.H. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea. Helicobacter 2020, 25, e12685. [Google Scholar] [CrossRef] [Green Version]
- Park, J.S.; Park, J.E.; Oh, B.S.; Yoon, B.W.; Kim, H.K.; Lee, J.W.; Kim, N.H.; Cho, W.S.; Woo, Y.S.; Jahng, J.; et al. Trend in the Eradication Rates of Helicobacter pylori Infection Over the Last 10 Years in West Gyeonggi-do, Korea: A Single Center Experience. Korean J. Gastroenterol. 2017, 70, 232–238. [Google Scholar] [CrossRef] [Green Version]
- Ierardi, E.; Giorgio, F.; Losurdo, G.; Di Leo, A.; Principi, M. How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography? World J. Gastroenterol. 2013, 19, 8168–8180. [Google Scholar] [CrossRef] [PubMed]
- Caldas, M.; Pérez-Aisa, Á.; Castro-Fernández, M.; Bujanda, L.; Lucendo, A.J.; Rodrigo, L.; Huguet, J.M.; Pérez-Lasala, J.; Molina-Infante, J.; Barrio, J.; et al. European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain. Antibiotics 2020, 10, 13. [Google Scholar] [CrossRef] [PubMed]
- Nyssen, O.P.; Bordin, D.; Tepes, B.; Pérez-Aisa, Á.; Vaira, D.; Caldas, M.; Bujanda, L.; Castro-Fernandez, M.; Lerang, F.; Leja, M.; et al. European Registry on Helicobacter pylori management (Hp-EuReg): Patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut 2021, 70, 40–54. [Google Scholar] [CrossRef]
- Van der Wouden, E.J.; Thijs, J.C.; van Zwet, A.A.; Sluiter, W.J.; Kleibeuker, J.H. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: A meta-analysis. Am. J. Gastroenterol. 1999, 94, 1751–1759. [Google Scholar] [CrossRef]
- Chung, J.W.; Lee, J.H.; Jung, H.Y.; Yun, S.C.; Oh, T.H.; Choi, K.D.; Song, H.J.; Lee, G.H.; Kim, J.H. Second-line Helicobacter pylori eradication: A randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy. Helicobacter 2011, 16, 289–294. [Google Scholar] [CrossRef] [PubMed]
- Lee, B.H.; Kim, N.; Hwang, T.J.; Lee, S.H.; Park, Y.S.; Hwang, J.H.; Kim, J.W.; Jeong, S.H.; Lee, D.H.; Jung, H.C.; et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: Effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010, 15, 38–45. [Google Scholar] [CrossRef]
- Yoon, J.H.; Baik, G.H.; Kim, Y.S.; Suk, K.T.; Shin, W.G.; Kim, K.H.; Kim, K.O.; Park, C.H.; Baik, I.H.; Jang, H.J.; et al. Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication. Gut Liver 2012, 6, 434–439. [Google Scholar] [CrossRef] [Green Version]
- Kim, T.H.; Park, J.M.; Cheung, D.Y.; Oh, J.H. Comparison of 7- and 14-Day Eradication Therapy for Helicobacter pylori with First- and Second-Line Regimen: Randomized Clinical Trial. J. Korean Med. Sci. 2020, 35, e33. [Google Scholar] [CrossRef]
- Kim, S.E.; Park, M.I.; Park, S.J.; Moon, W.; Kim, J.H.; Jung, K.; Kim, H.K.; Lee, Y.D. Second-line bismuth-containing quadruple therapy for Helicobacter pylori eradication and impact of diabetes. World J. Gastroenterol. 2017, 23, 1059–1066. [Google Scholar] [CrossRef]
- Suzuki, T.; Matsuo, K.; Ito, H.; Sawaki, A.; Hirose, K.; Wakai, K.; Sato, S.; Nakamura, T.; Yamao, K.; Ueda, R.; et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am. J. Med. 2006, 119, 217–224. [Google Scholar] [CrossRef] [PubMed]
- Graham, D.Y.; Lew, G.M.; Malaty, H.M.; Evans, D.G.; Evans, D.J., Jr.; Klein, P.D.; Alpert, L.C.; Genta, R.M. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992, 102, 493–496. [Google Scholar] [CrossRef]
- Itskoviz, D.; Boltin, D.; Leibovitzh, H.; Tsadok Perets, T.; Comaneshter, D.; Cohen, A.; Niv, Y.; Levi, Z. Smoking increases the likelihood of Helicobacter pylori treatment failure. Dig. Liver Dis. 2017, 49, 764–768. [Google Scholar] [CrossRef]
- Holm, L.; Perry, M.A. Role of blood flow in gastric acid secretion. Am. J. Physiol. 1988, 254, G281–G293. [Google Scholar] [CrossRef]
- Parente, F.; Lazzaroni, M.; Sangaletti, O.; Baroni, S.; Bianchi Porro, G. Cigarette smoking, gastric acid secretion, and serum pepsinogen I concentrations in duodenal ulcer patients. Gut 1985, 26, 1327–1332. [Google Scholar] [CrossRef] [Green Version]
- Zevin, S.; Benowitz, N.L. Drug interactions with tobacco smoking. An update. Clin. Pharmacokinet. 1999, 36, 425–438. [Google Scholar] [CrossRef]
- Shuter, J.; Bernstein, S.L. Cigarette smoking is an independent predictor of nonadherence in HIV-infected individuals receiving highly active antiretroviral therapy. Nicotine Tob. Res. 2008, 10, 731–736. [Google Scholar] [CrossRef]
- Ford, A.C.; Malfertheiner, P.; Giguere, M.; Santana, J.; Khan, M.; Moayyedi, P. Adverse events with bismuth salts for Helicobacter pylori eradication: Systematic review and meta-analysis. World J. Gastroenterol. 2008, 14, 7361–7370. [Google Scholar] [CrossRef] [PubMed]
- Mégraud, F. H pylori antibiotic resistance: Prevalence, importance, and advances in testing. Gut 2004, 53, 1374–1384. [Google Scholar] [CrossRef] [PubMed] [Green Version]
ITT | PP | |
---|---|---|
Number | 643 | 556 |
Age (y) mean ± SD | 57.1 ± 12.3 | 57.4 ± 12.2 |
Sex (%) | ||
Male | 265 (41.2) | 220 (39.6) |
Female | 378 (57.8) | 336 (60.4) |
Diabetes mellitus (%) | 80 (12.4) | 62 (11.2) |
Hypertension (%) | 139 (21.6) | 119 (21.4) |
Endoscopic findings (%) | ||
Peptic ulcer | 351 (54.6) | 299 (53.8) |
Gastritis | 276 (42.9) | 243 (43.7) |
EGCa + gastric adenoma | 16 (2.5) | 14 (2.5) |
Cigarette smoking (%) | 89/606 (14.7) | 70/525 (13.3) |
Alcohol intake (%) | 169/606 (27.9) | 142/525 (27.0) |
Year | Intention-to-Treat Eradicated/Total (%) | Per-Protocol Eradicated/Total (%) |
---|---|---|
2008~2011 | 97/133 (72.9) | 97/104 (93.3) |
2012~2015 | 233/289 (80.6) | 233/256 (91.0) |
2016~2019 | 189/221 (85.5) | 189/196 (96.4) |
Total | 519/643 (80.7) | 519/556 (93.3) |
Univariate Analysis | Multivariate Analysis | |||||
---|---|---|---|---|---|---|
OR | 95% CI | p-Value | OR | 95% CI | p-Value | |
Age (years) | 1.01 | 0.98, 1.04 | 0.620 | |||
Male (ref. Female) | 0.82 | 0.41, 1.64 | 0.569 | |||
Smoking (ref. never-smoker) | 2.92 | 1.36, 6.24 | 0.006 | 2.92 | 1.36, 6.24 | 0.006 |
Alcohol (ref. non-alcohol) | 0.90 | 0.41, 1.97 | 0.793 | |||
Type 2 Diabetes mellitus (ref. non-T2DM) | 0.96 | 0.33, 2.82 | 0.946 | |||
Hypertension (ref. non-hypertension) | 1.39 | 0.66, 2.97 | 0.389 | |||
10–14 days (ref. 7 days) | 0.44 | 0.13, 1.48 | 0.186 |
Patients (%), n = 562 | |
---|---|
Nausea, vomiting | 33 (5.9%) |
Loose stool, diarrhea | 20 (3.6%) |
Abdominal discomfort or pain | 14 (3.0%) |
Dyspepsia, poor oral intake | 12 (2.1%) |
Headache, dizziness | 11 (2.0%) |
Dry mouth | 6 (1.1%) |
General weakness | 6 (1.1%) |
Others | 10 (1.8%) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Shin, K.; Cho, M.-J.; Oh, J.-H.; Lim, C.-H. Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates. J. Clin. Med. 2021, 10, 3273. https://doi.org/10.3390/jcm10153273
Shin K, Cho M-J, Oh J-H, Lim C-H. Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates. Journal of Clinical Medicine. 2021; 10(15):3273. https://doi.org/10.3390/jcm10153273
Chicago/Turabian StyleShin, Kiwon, Min-Jae Cho, Jung-Hwan Oh, and Chul-Hyun Lim. 2021. "Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates" Journal of Clinical Medicine 10, no. 15: 3273. https://doi.org/10.3390/jcm10153273
APA StyleShin, K., Cho, M.-J., Oh, J.-H., & Lim, C.-H. (2021). Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates. Journal of Clinical Medicine, 10(15), 3273. https://doi.org/10.3390/jcm10153273